NCC-149

NCC-149 is a selective HDAC8 inhibitor and can be used for neural differentiation research[1].

Signaling Pathways >> Cell Cycle/DNA Damage >> HDAC

Research Areas >> Neurological Disease

Signaling Pathways >> Epigenetics >> HDAC

HDAC8

NCC-149 (5 μM, 3 days) remarkably reduces NeuN expression levels in P19 cells[1]. NCC-149 (0-40 μM, 4 days) reduces embryoid body size in a dose-dependent manner[1]. NCC-149 (5 and 20 μM, 24 h) downregulates P19 cell proliferation[1]. NCC-149 (2.5 and 5 μM, 24 h) leads to cell growth retardation by G2/M phase arrest[1]. Western Blot Analysis[1] Cell Line: P19 cells Concentration: 5 μM Incubation Time: 3 days Result: Remarkably reduced NeuN expression levels. Cell Proliferation Assay[1] Cell Line: P19 cells Concentration: 5 and 20 μM Incubation Time: 24 h Result: Downregulated cell proliferation. Cell Cycle Analysis[1] Cell Line: P19 cells Concentration: 2.5 and 5 μM Incubation Time: 24 h Result: Led to a significant increase in G2/M phase cells, with a slight decrease in S phase cells. RT-PCR[1] Cell Line: P19 cells Concentration: 25 μM or 2.5 and 5 μM Incubation Time: 4 days (25 μM) or 48 h (2.5 and 5 μM) Result: Did not reduce the HDAC8 expression at the mRNA level. Significantly and partially reduced cyclin B1 and cyclin A2 gene expression, respectively.

[1]. Katayama S, et al. HDAC8 regulates neural differentiation through embryoid body formation in P19 cells. Biochem Biophys Res Commun. 2018 Mar 25;498(1):45-51.